Rationale: Economic evaluations of pharmaceuticals require that health outcomes include adverse as well as beneficial effects of therapy. When the incidence and/or severity of adverse drug reactions (ADRs) result in an unfavourable risk/benefit profile, regulatory authorities such as the EMEA...